[
  {
    "ts": null,
    "headline": "IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes",
    "summary": "CONSHOHOCKEN, Pa., October 16, 2025--IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansion, IntrinsiQ is now also offering oncology biomarker data, enabling physicians to transition from a generalized treatment approach to precision medicine. This critical data allows physicians to tailor cancer therapies to the individual needs of e",
    "url": "https://finnhub.io/api/news?id=ca3f65401a18da6649f6861ab1b7a00f56afb53054039f900b5e61e6a16c55cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619600,
      "headline": "IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes",
      "id": 137104735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "CONSHOHOCKEN, Pa., October 16, 2025--IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansion, IntrinsiQ is now also offering oncology biomarker data, enabling physicians to transition from a generalized treatment approach to precision medicine. This critical data allows physicians to tailor cancer therapies to the individual needs of e",
      "url": "https://finnhub.io/api/news?id=ca3f65401a18da6649f6861ab1b7a00f56afb53054039f900b5e61e6a16c55cf"
    }
  },
  {
    "ts": null,
    "headline": "Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US",
    "summary": "DETROIT, October 16, 2025--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a specialty distribution network from McKesson, Cencora, and Cardinal Health.",
    "url": "https://finnhub.io/api/news?id=af5bcbe3e88f76306f1ead52f0151a323c3a2131485bff5935234082c9a03449",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619600,
      "headline": "Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US",
      "id": 137104649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "DETROIT, October 16, 2025--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a specialty distribution network from McKesson, Cencora, and Cardinal Health.",
      "url": "https://finnhub.io/api/news?id=af5bcbe3e88f76306f1ead52f0151a323c3a2131485bff5935234082c9a03449"
    }
  }
]